Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
Shiu
Jennifer R
JR
Romanick
Marcel
M
Stobart
Kent
K
D000293:Adolescent; D000932:Antiemetics / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000493:pharmacokinetics; D000077608:Aprepitant; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D004347:Drug Interactions; D005047:Etoposide / Q000009:adverse effects / Q000493:pharmacokinetics; D005334:Fever / Q000209:etiology; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000493:pharmacokinetics; D015994:Incidence; D009025:Morpholines / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D018401:Sample Size; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D009025:Morpholines; D000077608:Aprepitant; D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide